Allogene Therapeutics, Inc. (NASDAQ:ALLO) CEO Sells $91,469.28 in Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) CEO David D. Chang sold 46,668 shares of Allogene Therapeutics stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $1.96, for a total transaction of $91,469.28. Following the transaction, the chief executive officer now owns 5,276,569 shares of the company’s stock, valued at approximately $10,342,075.24. The trade was a 0.88 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Allogene Therapeutics Stock Performance

Allogene Therapeutics stock opened at $1.63 on Friday. Allogene Therapeutics, Inc. has a 1 year low of $1.32 and a 1 year high of $4.63. The firm has a 50 day moving average price of $1.89 and a 200 day moving average price of $2.29. The company has a market cap of $354.14 million, a price-to-earnings ratio of -1.04 and a beta of 1.02.

Allogene Therapeutics (NASDAQ:ALLO) last released its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06. Sell-side analysts predict that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

Institutional Investors Weigh In On Allogene Therapeutics

Institutional investors have recently bought and sold shares of the business. Cibc World Markets Corp purchased a new stake in Allogene Therapeutics during the fourth quarter worth approximately $26,000. PAX Financial Group LLC purchased a new stake in Allogene Therapeutics during the fourth quarter worth approximately $27,000. RPO LLC purchased a new stake in Allogene Therapeutics during the fourth quarter worth approximately $31,000. Caption Management LLC purchased a new stake in Allogene Therapeutics during the fourth quarter worth approximately $32,000. Finally, Syon Capital LLC purchased a new stake in Allogene Therapeutics during the fourth quarter worth approximately $39,000. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ALLO has been the subject of a number of recent research reports. HC Wainwright lowered their price target on shares of Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price target on shares of Allogene Therapeutics in a report on Friday, March 14th. Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a report on Friday, March 14th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a report on Friday, March 14th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $9.29.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).